Hinduja Foundation signs MoU with Dr Mane Medical Foundation

IMT News Desk
IMT News Desk
· 2 min read

Launch free cancer screening programme for underprivileged women in Shirdi

Hinduja Foundation, the philanthropic arm of the Hinduja Group, has signed a Memorandum of Understanding (MoU) with Dr Mane Medical Foundation & Research Centre, an NGO based in Ahmednagar, Maharashtra. The partnership marks the launch of a comprehensive cancer screening and awareness programme, offered entirely free of cost, in Shirdi and other districts of Maharashtra.

This grassroots initiative aims to screen 10,000 ultra-poor women for cervical and breast cancer by December 2025. The first screening camp was held on June 8 at Rahuri, 60 kms from Shirdi, where nearly 350 women were screened.

Focussed on early detection and timely intervention, the programme addresses a critical gap in access to preventive healthcare for marginalised groups who often go undiagnosed due to financial and geographical barriers.

Dr Mane Medical Foundation will lead on-ground implementation, supported by community outreach efforts. All women will undergo Pap Smear and Clinical Breast Examination (CBE), and where needed, additional health checks including haemoglobin, blood sugar and cholesterol tests.

Namrata Hinduja, Member, Steering Committee of Hinduja Foundation, said, “Empowering women through health is the foundation of building stronger communities. This initiative reaffirms our unwavering commitment to closing critical healthcare gaps and ensuring that no woman is denied care because of her economic circumstances.”

Paul Abraham, President, Hinduja Foundation, said, “Cancer has emerged as the fastest-growing health concern in India, with over 1.7 million new cases reported in 2025. Projections indicate that this number could rise to 2.5 million by 2030. Early detection through screening is key to managing costs and survival chances. This initiative is not just about early detection & treatment, but also about education, empowerment, and building a culture of preventive care. We are committed to creating a lasting impact in communities that need it the most.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk